Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses
Benzinga Newsdesk 1 week ago
News
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced
- EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses
- Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial
- The data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings